Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements - Narrative (Details)

v3.24.2.u1
Fair Value Measurements - Narrative (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
item
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jul. 01, 2022
USD ($)
May 31, 2021
USD ($)
Apr. 06, 2021
USD ($)
Income Tax Expense (Benefit), Total   $ 17,584 $ 53,217 $ 38,287          
Exchange Traded Investment Grade Bond Funds                  
Investments, Total     25,000            
Investments, Fair Value Disclosure, Total     23,700            
Asuragen, Inc.                  
Contingent consideration     2,000           $ 18,300
Maximum contingent consideration         $ 105,000        
Namocell Inc                  
Contingent consideration     $ 1,500       $ 10,600    
Maximum contingent consideration         $ 25,000   $ 25,000    
Forward starting swaps | Cash flow hedges | Designated as hedging instruments                  
Derivative, Notional Amount           $ 100,000   $ 200,000  
Cross-currency swap | Net investment hedge | Designated as hedging instruments                  
Derivative, Notional Amount $ 150,000                
Number of interim settlement dates | item 4                
Notional amount at maturity $ 110,000                
Derivative Notional Amount, Decrease in Period $ 10,000